#peak-trial
Latest news and interesting information about peak-trial.
Cogent Stock Price Target Raised to $55
Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.
...
